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p300 and CBP are multi-domain histone acetyltransferases (HATs) that regulate gene expression and are
mutated in human diseases including cancer. Delvecchio and colleagues report the structure of the p300 cata-
lytic core, revealing the presence of a previously unknown RING domain that regulates the enzyme’s activity.Figure 1. p300 Domains and Oncogenic Mutations
Domain structure of p300 overlaid with mutations and truncations found in solid tumors and lymphoid
neoplasms (Iyer et al., 2004; Pasqualucci et al., 2011). The catalytic core of p300 is a hotspot for cancer
mutations.Reversible acetylation of lysine residues
on histones, transcription factors, and
transcriptional coactivators plays a central
role in activating eukaryotic transcription
(Eberharter and Becker, 2002). Histone
acetyltransferase (HAT) enzymes catalyze
lysine acetylation and are grouped into
three main families based on sequence
homology within their catalytic domains:
the Gcn5 N-acetyltransferase (GNAT)
family, the Morf, Ybf2, Sas2, and Tip60
(MYST) family, and the p300/CBP family
(Lee and Workman, 2007). Although all
three classes of HATs use acetyl-CoA as
the acetyl donor and catalyze the same
reaction, they differ substantially in struc-
ture and use different reaction mecha-
nisms (Berndsen and Denu, 2008). A
variety of mechanisms have evolved to
regulate acetyltransferase activity and
prevent inappropriate gene activation.
These mechanisms include incorporation
of the HAT into larger complexes that
potentiate its enzymatic activity and the
presence of one or more chromatin reader
domains, which each recognize a specific
type of histone modification (Lee and
Workman, 2007). By binding to individual
histone modifications, such as acetylated
or methylated lysine, or to combinations
of modifications, chromatin reader do-
mains restrict HAT activity to the appro-
priate chromosomal context (Lee and
Workman, 2007). Misregulation of enzy-
matic activity has been associated with
cancer for all three HAT families, and
manyaggressive tumorsarecharacterized
by differences in HAT expression levels
(Cohen et al., 2011).
CBP and p300 are large, highly similar
HATs of over 2,400 amino acid residues
with overlapping cellular functions. The
two proteins are 64% identical in pri-
mary sequence, with even greater levelsof conservation across their catalytic
cores (Kalkhoven, 2004). p300/CBP con-
tains at least nine annotated domains, in
addition to the HAT domain, including a
bromodomain, which binds acetylated
lysines (Kalkhoven, 2004), and a pre-
dicted PHD domain, which typically binds
methylated lysines (Lee and Workman,
2007). In addition to associating with tran-
scription factors such as TATA-binding
protein and TFIIB, p300/CBP also inter-
acts with tumor suppressor proteins, like
p53 and BRCA1, as well as oncoproteinsStructure 21, September 3, 2013 ªsuch as fos and myb (Kalkhoven, 2004).
Among HAT enzymes, p300/CBP is
particularly interesting because it acti-
vates itself by autoacetylating a basic
loop in the HAT domain (Thompson et al.,
2004) and also acetylates at least 70 non-
histone proteins, including p53 (Wang
et al., 2008). Mutations in CBP give rise
to the congenital development disorder,
Rubinstein-Taybi Syndrome (RTS) (Kalk-
hoven, 2004), andmultiple humancancers
arise frommutations and translocations of
p300/CBP (Figure 1). While an earlier2013 Elsevier Ltd All rights reserved 1479
Figure 2. Structure of p300 Core Fragment
Individual domains colored as in Figure 1.Certain p300mutations found in can-
cer map to the newly discovered autoinhibitory RING domain. C1204R coordi-
nates a zinc atom in the RING domain itself, whereas E1242 and R1645 form a
salt bridge between the RING and HAT domains. (PDB ID 4BHW).
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Previewstructure of the isolated p300
HAT domain showed how
certain oncogenic mutations
disrupted catalytic activity
(Liu et al., 2008), most known
mutations and deletions
either map outside of this
domain or have no obvious
impact on catalytic function
(Cohen et al., 2011; Kalk-
hoven, 2004). Given our cur-
rent understanding of p300/
CBP-catalyzed acetylation,
the mechanism by which
these core mutations dysre-
gulate the acetyltransferase
activity of p300/CBP and
contribute to carcinogenesis
has remained elusive.
The structure reported by
Delvecchio et al. (2013) of a
larger p300 catalytic core
fragment contains an unan-ticipated feature that is key to under-
standing p300/CBP HAT regulation. In
addition to the HAT domain bound to a
lysine-CoA bisubstrate analog, the frag-
ment also contains a bromodomain and
a sequence known as the CH2 region,
which contains a PHD domain. The struc-
ture quite unexpectedly revealed that the
CH2 region also contains a structurally
unusual RING domain, which is inserted
within the PHD domain. RING domains
are found in a subset of ubiquitin E3
ligases, where they mediate interactions
with both E2 ubiquitin conjugating
enzymes and ubiquitin (Deshaies and
Joazeiro, 2009). In the new p300 struc-
ture, the RING domain contacts the active
site of the HAT domain and blocks the
substrate-binding cleft, thus suggesting
that the RING domain might regulate
HAT activity. Indeed, the authors showed
that mutating key residues that perturb
binding of the RING domain to the HAT
domain results in a hyperactive form of
the enzyme, pointing to an autoinhibitory
role for the RING domain in p300/CBP
catalysis. A number of mutations and de-
letions that give rise to cancer and RTS
also map to the RING-HAT interface, illu-
minating the likely mechanism by which
previously uncharacterized mutations
misregulate p300/CBP activity and cause
disease. For example, the C1204R muta-
tion found in some B cell lymphomas
disrupts the integrity of the RING domain
by removing a zinc coordination site1480 Structure 21, September 3, 2013 ª2013(Figure 2). Other curated mutations affect
the RING domain as well; mutations that
disturb the interaction between the RING
and active site, such as R1645E and
E1242K, are found in malignant mela-
noma and RTS, respectively (Figure 2),
while the RING is entirely deleted in
some forms of breast cancer. Accord-
ingly, cells transfected with any of these
mutant enzymes display hyperacetylation
of p53 relative to a wild-type control.
Why was the presence of the RING
domain in p300/CBP overlooked? First,
the RING is embedded in a PHD domain,
whose histone-interacting residues have
been rearranged as a result. Second,
while canonical RING domains contain
two structural zinc atoms in separate
coordination sites (Deshaies and Joa-
zeiro, 2009), the p300 RING contains a
single bound zinc, with tightly packed
hydrophobic interactions replacing the
second metal-binding site. There is also
an insertion in the p300 RING loop L2
that, in other RINGs, interacts with E2
enzymes (Deshaies and Joazeiro, 2009).
Based on its established role in the ubiq-
uitin conjugation pathway, Delvecchio
et al. (2013) tested the p300 RING for E3
ligase activity in vitro but could detect
none, at least with the panel of E2 en-
zymes tested. Although an as-yet undis-
covered role in ubiquitination cannot be
ruled out, the authors’ findings indicate
that the RING domain in p300 has been
adapted to autoregulate HAT activity.Elsevier Ltd All rights reservedThe discovery of a previ-
ously unknown RING domain
that gates the activity of the
HAT domain is a key step for-
ward in understanding how
p300 is regulated. It remains
to be seen to what degree
the RING domain may core-
gulate HAT activity in concert
with the autoregulatory loop
in the HAT domain, which
was deleted in both the pre-
sent and previous (Liu et al.,
2008) structural studies of
p300 because it interfered
with crystallization. The role
of the PHD domain also re-
mains to be determined,
because it lacks features that
enable other PHD domain to
bind methylated lysines on
histones. Perhaps this PHD
domain evolved to perform astructural role, anchoring the inserted
RING domain near the catalytic site and
forming a compact core structure that
bridges the bromodomain and catalytic
domain. Although the newly identified
RING domain does not appear to be an
active member of the ubiquitination ma-
chinery, previous work has shown that
the first 600 residues of p300/CBP
have E3 ligase activity and mediate
ubiquitination of the tumor suppressor
protein p53 (Grossman et al., 2003).
Could it be that this portion of p300/CBP
also contains a divergent RING that is
not detectable by primary sequence anal-
ysis? More broadly, the discovery of an
unanticipated domain that plays a
critical role in regulating HAT activity
is a reminder that other such domains
likely await discovery. The inventory
of regulatory mechanisms applied to
HATs will surely continue to grow as
structural biologists successfully tackle
larger and larger protein fragments and
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